ReviewMedical oncology (Northwood, London, England)2025
A review on the advancement of polydopamine (PDA)-based nanomaterials for cancer treatment.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Construction of polyethylene glycol-cloaked mesoporous polydopamine nanomaterials co-loaded with anticancer drugs for photo/chemotherapy of lung cancer cells and elucidation of the cell death mechanism.Journal of materials science. Materials in medicine · 2026Article
- From structural complexity to circular applications: a comparative review of the enzymatic degradation of polydopamine, tannins, lignins, and melanins.RSC advances · 2026Review
- Fabrication of size-tunable polydopamine nanoparticles: toxicity evaluation in cellular and animal models.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Multifunctional thermosensitive hydrogel for synergistic antibacterial, anti-inflammatory and osteogenic effects to promote periodontal regeneration in periodontitis treatment.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The significance of cancer treatment research lies in addressing the high incidence of cancer, overcoming treatment challenges, and mitigating the harsh side effects of chemotherapeutic agents. Currently, nanotechnology is garnering significant attention for its potential applications in diagnostics and drug delivery, offering innovative solutions for disease detection and treatment. Among different types of nanoparticles (NPs), polymeric nanoparticles comprise biocompatible and biodegradable polymers that enhance drug pharmacokinetics and pharmacodynamics, minimize adverse effects, increase stability, and facilitate sustained drug release. These polymeric nanoparticle-based nanomedicines offer a versatile platform for various cancer treatments, notably enabling targeted drug delivery directly to tumors, tumor-imaging, hyperthermia, and photodynamic therapy. Being polymeric in nature polydopamine (PDA) nanomaterials are appeared as promising approaches in biology and medicine. This review article offers a concise summary of the latest developments in polydopamine-based cancer treatment, covering key findings, limitations, and emerging trend therapeutic approach of polydopamine nanomaterials, along with the properties and various methods of preparation. Physico-chemical properties of PDA-based nanomaterials in therapeutics have permitted several successful modifications in the field of cancer treatment.
Indexed as
Identifiers
40237855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.